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Abstract
To account for between-study heterogeneity in meta-analysis of diagnostic accuracy studies, 
bivariate random effects models have been recommended to jointly model the sensitivities and 
specificities. As study design and population vary, the definition of disease status or severity could 
differ across studies. Consequently, sensitivity and specificity may be correlated with disease 
prevalence. To account for this dependence, a trivariate random effects model had been proposed. 
However, the proposed approach can only include cohort studies with information estimating 
study-specific disease prevalence. In addition, some diagnostic accuracy studies only select a 
subset of samples to be verified by the reference test. It is known that ignoring unverified subjects 
may lead to partial verification bias in the estimation of prevalence, sensitivities and specificities 
in a single study. However, the impact of this bias on a meta-analysis has not been investigated. In 
this paper, we propose a novel hybrid Bayesian hierarchical model combining cohort and case-
control studies and correcting partial verification bias at the same time. We investigate the 
performance of the proposed methods through a set of simulation studies. Two case studies on 
assessing the diagnostic accuracy of gadolinium-enhanced magnetic resonance imaging in 
detecting lymph node metastases and of adrenal fluorine-18 fluorodeoxyglucose positron emission 
tomography in characterizing adrenal masses are presented.
Keywords
Bayesian method; cohort and case-control studies; diagnostic test; partial verification bias; meta-
analysis
1 Introduction
Accurate diagnosis of a disease is often the first step toward its treatment and prevention. 
The growing number of assessment instruments, as well as a rapid escalation in costs has 
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generated an increasing need for scientifically rigorous comparisons of the diagnostic tests 
in clinical practice. In the presence of a gold standard measure of disease status, the 
performance of a binary diagnostic test is often measured by paired indices, such as 
sensitivity (Se) and specificity (Sp), positive and negative predictive values (PPV and NPV), 
or positive and negative diagnostic likelihood ratios (LR+ and LR−).1,2 Sensitivity and 
specificity are often regarded as intrinsic properties of a diagnostic test. However, it is well 
understood that Se and Sp may not reflect the clinical utility of a diagnostic test; such 
clinical utility depends on the prevalence of disease (π) in the population to which the 
instrument is applied.3 In particular, high NPV or a low LR− is necessary for a diagnostic 
test to be useful at ruling out disease, and high PPV or a high LR+ is necessary for a 
diagnostic test to be useful at confirming disease.
Meta-analysis of diagnostic tests is a useful tool to combine evidence on diagnostic 
accuracies from multiple studies. Compared to conventional meta-analyses of controlled 
clinical trials, it has several additional statistical challenges. Specifically, the paired indices 
are typically correlated and heterogeneous across studies due to differences in study design, 
population selection, or laboratory methods.4–13 Bivariate random effects models on 
sensitivities and specificities have been recommended to account for such correlation and 
heterogeneity in the literature and specifically by the Cochrane Diagnostic Methods 
group.8,10,11 In addition, because the classification of disease status is typically based on a 
continuum of measurable traits, and such continuous traits not only determine disease 
prevalence, but also misclassification rates (subjects with true levels close to the cut-point 
are more likely to be misclassified), sensitivities and specificities can be correlated with 
study prevalences.14 Trivariate random effects models on prevalence, sensitivities and 
specificities were proposed to account for such correlations.15 However, many meta-
analyses of diagnostic tests in practice contain both cohort and case-control study designs.16 
Using cohort design, a study first tests participants with the index test, next confirms disease 
status with the gold standard.17 In case-control design studies, groups of patients with and 
without disease are identified before performing the index test.18 Thus, case-control studies 
cannot be used to estimate disease prevalence and direct application of the trivariate random 
effects models has been restricted to a meta-analysis with cohort studies only. Under such 
situations, ignoring the information on prevalence to fit the bivariate random effects 
model6,9–11 on Se and Sp, or excluding case-control studies to fit the trivariate random 
effects model15 on prevalence can potentially lead to substantial loss of information 
contained in the data. For example, the former approach ignores disease prevalence 
information and the correlations between disease prevalence Se and Sp, which can lead to 
incorrect estimation of PPV and NPV.
Partial verification is a common and important potential source of bias that usually arises 
when the selection of samples to be verified by a reference standard test is affected by the 
results of a diagnostic test.19,20 As stated in the quality assessment tool for diagnostic 
accuracy studies (QUADAS), partial verification bias occurs when not all of the study group 
receive confirmation of the diagnosis by the reference standard.21 As an illustration, let us 
assume that the true Se and Sp of a diagnostic test are 0.8 and 0.9, respectively. A study with 
a population of 100 diseased (D+) and 200 non-diseased (D−) subjects is conducted to 
evaluate the diagnostic test performance. Assume 80% of the subjects with test positive 
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outcomes are verified, while only 20% of the subjects with test negative outcomes are 
verified by a reference standard. Let ntd denote the number of subjects with test results T = t 
and disease status D = d (t, d = 0, 1, m indicating negative, positive and missing results, 
respectively). Assuming no sampling variation, we will have n11 = 64, n01 = 4, n00 = 36, n10 
= 16, n1m = 20 and n0m = 160. Now, if we only use verified samples, we overestimate Se as 
 and underestimate Sp as . Moreover, 
the direction and magnitude of such bias depends on selection probabilities.22 To avoid such 
bias, ideally, all subjects should be verified. However, due to some practical issues such as 
ethical and economic considerations, partial verification is prevalent. In a systematic review 
of bias and variation in meta-analysis of diagnostic accuracy studies, 15 out of 31 (48%) 
meta-analyses contain at least one study with partial verification.22 Thus, it is important to 
adjust for partial verification bias in meta-analysis of diagnostic tests.22,23
Methods to adjust for verification bias in a single study are widely published. Most of the 
methods are built upon the missing at random (MAR) assumption, when the decision to 
ascertain disease status only depends on the observed index test result, T. Violations of this 
condition can happen when, for example, subjects with family disease history are more 
likely to get disease status verified.1 Begg and Greenes24 proposed a simple method based 
on Bayes theorem. Other methods such as multiple imputation, direct maximum likelihood, 
or Bayesian approaches have been proposed.20,25–29 These methods give unbiased estimates 
of Se and Sp for individual studies instead of recovering missing counts of subjects. Thus we 
would not be able to apply the exact binomial likelihood assumption for a GLMM approach 
under meta-analysis settings. Few sensitivity analysis methods are available under the 
assumption of Missing Not At Random (MNAR), i.e., the probability of being verified by a 
reference standard depends on the unobserved data.30,31
On the other hand, only limited literature are available on methods to adjust verification bias 
in a meta-analysis setting. De Groot et al.32 extended the Bayes theorem method to adjusting 
for this bias in meta-analysis of diagnostic tests with nominal outcomes. A two-stage 
Bayesian approach was described, where in the 1st stage the probability distribution of the 
index test was calculated and in the 2nd stage PPV and NPV are calculated using observed 
data based on their unbiasedness property under the MAR assumption.1 Bayes theorem is 
then applied to achieve pooled sensitivity and specificity estimates. A few papers have 
discussed the missing data problem caused by imperfect reference standards, but these 
papers are not aimed at partial verification problems specifically. Chu et al.33 discussed a 
latent class random effects model for such a scenario. The model allows variation in 
sensitivity, specificity and prevalence across different studies, and allows correlation among 
the parameters. Sadatsafavi et al.34 proposed a random effects model which allows either 
sensitivity or specificity to vary across studies.
To the best of our knowledge, no one has considered methods to combine information from 
cohort and case-control studies, and to correct partial verification bias in meta-analyses of 
diagnostic tests simultaneously. In this paper we propose a hybrid generalized linear mixed 
model (hybrid GLMM) to solve the two problems together under the assumption of a gold 
standard reference test. The proposed method is described in Section 2. Simulation studies 
are carried out and reported in Section 3. Section 4 provides two motivating case studies. 
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The paper ends with a discussion in Section 5. The data sets for the two case studies are 
given in Appendix 1, Tables S1 and S2, and corresponding WinBUGS code are given in 
Appendix, respectively.
2 Bayesian Hierarchical Model
2.1 Notations
Suppose that we have a meta-analysis with N diagnostic accuracy studies, and the studies are 
indexed such that the N1 cohort studies come first, followed by N2 = N − N1 case-control 
studies. To allow partial verification in some of the first N1 cohort studies, let nitd be the 
number of subjects with disease status D = d and test results T = t (d, t = 0, 1, m indicating 
negative, positive and missing results, respectively) in the ith study (i = 1, 2, …, N1) and pitd 
be the corresponding probability. As subjects with both D and T missing do not provide any 
information, we will not consider them. Let πi, Sei and Spi denote disease prevalence, 
sensitivity and specificity for study i such that πi = P (D = 1), Sei = P(T = 1|D = 1) and Spi = 
P(T = 0|D = 0). Let V = 1 and V = 0 denote the subject is verified or not, respectively. Let 
ωitm (t = 0, 1) and ωimd (d = 0, 1) be the mutually exclusive probabilities of missing for 
subjects with test result T = t and disease status D = d, respectively. Furthermore, given the 
nature of case-control studies, it is unnecessary to consider the influence of missing data in 
case-control studies: subjects with unverified disease status generally do not exist and 
subjects with missing diagnostic test outcomes can be ignored as prevalences in such studies 
are not well defined.
Table 1 presents the data structure and notation for the ith study when it is a cohort study or 
a case-control study. In each cell, the number of cell counts and the corresponding 
probabilities are presented. The left panel is for a cohort studies, which extends a standard 2 
× 2 table to allow for partial verification. The sum of all cell probabilities is one. The right 
half is for a case-control studies with a typical 2 × 2 table. The cell probabilities sum up to 
one for diseased and non-diseased subjects respectively. Derivations of the cell probabilities 
for cohort studies are also provided at the footnote of Table 1.
2.2 The Likelihood with Random Effects Accounting for Heterogeneity
Let ω= {ωi} and θ= {θi}, where ωi = (ωi0m, ωi1m, ωim0, ωim1) and θi= (πi, Sei, Spi) for 
study i. Assuming independence among subjects conditional on θi and ωi, the likelihood is 
the product of contribution from each study. Multinomial likelihoods are used for cohort 
studies and binomial likelihoods are used for case-control studies. In this paper we assume 
verification is MAR, where the missing probabilities ω are independent of prevalence and 
test accuracy parameters, θ. Therefore, the likelihood can be factored as L(θ, ω|Data) ∝ L(θ|
Data) × L(ω|Data). Specifically,
(1)
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and
(2)
where hi1 = πiSei + (1 − πi)(1 − Spi), hi0 = πi(1 − Sei) + (1 − πi)Spi and j = 0, 1, m.
To account for potential between-study heterogeneity, we consider a generalized linear 
mixed effects model (GLMM):
(3)
where g() is a link function such as logit or probit, and (εi, μi, νi)T is a vector of random 
effects. To account for potential correlation among πi, Sei and Spi, the random effects (εi, μi, 
νi)T are assumed to follow a multivariate normally distribution as (εi, μi, νi)T ~ N(0, Σ), 
where
The diagonal elements of the variance-covariance matrix Σ, ( ), characterize the 
between-study heterogeneities of disease prevalence, test sensitivities and specificities, while 
the off diagonal elements (ρεμ, ρεν, ρμν) capture the correlations between the corresponding 
random effects (πi, Sei), (πi, Spi) and (Sei, Spi) in the transformed scale, respectively. For 
simplicity, we assume the same correlation structure for sensitivities, specificities and 
prevalences for both case-control and cohort studies in this paper, which can be easily 
relaxed if necessary. However, for case-control studies, the study-specific prevalences are 
not contained in the likelihood and not directly estimable, and can be predicted using this 
correlation structure and study-specific sensitivity and specificity.
Study-level covariates, such as study quality, type of design (case-control versus cohort 
studies), race distribution and mean age, can be incorporated through meta-regression when 
necessary. For example, let g(πi) = η0 + η1Xi + εi, g(Sei) = α0 + α1Wi+ μi and g(Spi) = β0 + 
β1Zi + νi, where Xi, Wi and Zi denote the possibly overlapping study-level covariate vectors. 
Note that the hybrid GLMM accounts for different study designs in the construction of 
likelihood. Including type of study design as a covariate is helpful when there is a systematic 
difference between cohort and case-control studies, e. g., if the pooled sensitivity and 
specificity are believed to be different between the two designs.
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The marginal likelihood integrated over random effects is:
(4)
Frequentist methods (such as the maximum likelihood estimate) may converge slowly or 
have convergence problems due to the need to maximize the marginal likelihood with 
trivariate integrations, and the corresponding asymptotic approximations for standard errors 
of functions of parameters may not be sufficiently accurate.35
2.3 Bayesian Posterior Sampling approach
In this paper, we consider fully Bayesian approaches using Markov chain Monte Carlo 
(MCMC) methods for parameter estimation. In most instances, inferences obtained by 
Bayesian and classical frequentist methods are similar when the former uses non-
informative or weakly informative prior distributions for all model parameters.36 Compared 
to the frequentist methods, MCMC algorithms permit full posterior inference (e.g., credible 
intervals (CrIs)) even when the normality approximation based on large sample theory is 
insufficient, which is valuable here because the sampling distributions of π, Se, Sp, PPV, 
NPV, LR+ and LR− are often skewed and the number of studies in the meta-analysis is 
typically small or moderate (e.g., N < 30). Specifically, we will draw posterior inference 
using Gibbs and Metropolis-Hastings sampling algorithms37–40 with convergence assessed 
using trace plots, sample autocorrelations, and statistical convergence diagnostic tests.41,42
Let p(η), p(α), p(β) and p(Σ) denote the prior distributions for η, α, β and Σ. We take non-
informative normal priors on η, α, β and a Wishart prior on the precision matrix Σ−1 (inverse 
Wishart prior on Σ), denoted by
(5)
where R is a 3 by 3 matrix, and a small number is chosen as the degrees of freedom v (v ≥ 
3). The posterior distribution of η, α, β and Σ can be written as:
(6)
where L(θ|data) depends on (η, α, β) through πi= g−1(η + εi), Sei = g−1(α + μi) and Spi = 
g−1(β + νi), and g−1(·) is the inverse function of the link function g(·). When study-level 
covariates are included in the link functions, plug in πi = g−1(η0 + η1Xi + εi), Sei = g−1 (α0 
+ α1Wi + μi) and Spi = g−1(β0 + β1Zi + νi) instead. Here we focus on the model without 
covariates for simplicity of the presentation.
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Using the MCMC samples of η, α, and β, the posterior samples for population-averaged 
PPV, NPV, LR+, LR− can be approximated by the following formulas:
3 Simulation
3.1 Simulation Design
We conduct 12 sets of simulations to compare the proposed Bayesian hybrid GLMM (model 
1) to two alternative approaches which researchers are likely to apply in practice: 1) a 
complete case analysis approach in which subjects not verified are ignored (model 2); and 2) 
a trivariate GLMM approach in which case-control studies are excluded from the analysis 
(model 3). To fit model 2, case-control and cohort studies are combined as in the hybrid 
GLMM, while the missing counts are excluded. To fit model 3, the missing counts are 
accounted for as in the hybrid GLMM, while all case-control studies are excluded from the 
data. To investigate the performance of the proposed hybrid GLMM, for each generated 
dataset, we fit the hybrid GLMM, model 2 and model 3 separately using R package 
BRugs.43 Each dataset contains equal numbers of case-control and cohort studies, where 
cohort studies are subject to partial verification. The probabilities of missing a reference test 
are 0.2 and 0.8, given diagnostic test results being positive and negative, respectively. The 
median prevalence is set to be 0.2 with the variances as , and the number of 
subjects per study is chosen to be similar to the case studies in Section 4. Specifically, we 
consider 12 settings with small (10) or moderate (30) number of studies in a meta-analysis 
and high sensitivity (specificity) as 0.9 (0.95), or low sensitivity (specificity) as 0.7 (0.8), 
respectively. To evaluate the impact of the correlation structure, the correlation parameters 
(ρεμ,ρεν, ρμν) are chosen as (0, 0, 0), (0.5, −0.5, −0.5) or (0.8, −0.8, −0.8) to correspond to 
no correlation, moderate or strong correlations among disease prevalence and test sensitivity 
and specificity (in logit scale). We assume a positive correlation between πi and Sei as it is 
likely to happen when population with higher prevalence may have more patients with clear-
cut disease condition, leading to a higher sensitivity. However, a negative correlation was 
also observed in some studies.14 For each setting, 2000 replicates are generated using the 
trivariate logit-normal random effects model. The posterior statistics (median and 95% equal 
tailed CrI) are summarized from 10000 posterior samples with 5000 burn-in iterations. 
Model performance is evaluated by comparing bias, relative efficiency (RE) and 95% equal 
tailed CrI coverage probability (CP) of the three models. The REs are calculated as the ratio 
of the variances of estimates from the hybrid model and the variances of the estimates from 
an alternative model. The larger RE, the more efficient the estimate from that alternative 
model.
3.2 Simulation Results
We summarized in Table 2 the bias, RE and CP of estimated overall Se, Sp, π, NPV and 
PPV for settings with 30 studies and median Se (Sp) as 0.7 (0.8). Simulation results under 
Ma et al. Page 7
Stat Methods Med Res. Author manuscript; available in PMC 2016 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
other simulation settings are summarized in Appendix 2 Tables S3–S5. Under all settings, 
the hybrid GLMM gives nearly unbiased estimates and satisfactory CP of Se, Sp, π, PPV 
and NPV that are close to the nominal level of 95%.
As expected, when the partial verification is ignored as in model 2, some of the posterior 
estimates were considerably biased with grossly small CP. Under our simulation 
assumptions, specificities are under-estimated, and prevalences and sensitivities are 
overestimated, which agrees with the illustrative example described in the introduction. An 
intuitive explanation is that if we assume ωi1m = 0 and ωi0m > 0 such that partial verification 
would decrease ni10 and ni00 but ni11 and ni10 remain the same, leading to increased Se and 
decreased Sp estimates. From the simulations we also observe that the bias in π is larger 
when true Se (Sp) was 0.9 (0.95) (ranges from 0.13 to 0.2) than when true Se (Sp) was 0.7 
(0.8) (ranges from 0.04 to 0.11), respectively. On the contrary, Sp and Se estimates are more 
biased when true Se (Sp) is 0.7 (0.8) (ranges from 0.04 to 0.14 and from 0.09 to 0.11 
respectively) than when true Se (Sp) is 0.9 (0.95) (ranges from 0.01 to 0.04 and from 0.03 to 
0.04 respectively). Because the estimates are biased, we do not calculate the RE of these 
estimates. Estimates of PPV and NPV from model 2 are nearly unbiased. Under the MAR 
assumption, we have P(V = 1|D = 1, T = 1) = P(V = 1|T = 1), where V = 1 indicates 
verification of disease status, which would imply that P(D = 1|V = 1, Y = 1) = P(D = 1|Y = 
1).1
When only cohort studies are included as in model 3, the estimates are nearly unbiased and 
the CPs remain close to the nominal level. Specifically, for estimation of prevalence, when 
there is no correlation, model 3 performs as well as the hybrid GLMM because only the 
cohort studies have information of π. However, as the correlation becomes larger, the RE of 
model 3 becomes smaller indicating the hybrid GLMM is gaining efficiency. This is because 
information of estimating prevalence is borrowed from Se and Sp estimates from case-
control studies. For estimations of Se and Sp, substantial loss of efficiency can be observed 
using model 3 with REs around 0.3 and 0.5. The reason is that half of the whole study set 
(the case-control studies) are discarded in model 3, which contains important information to 
estimate Se and Sp. For estimations of PPV and NPV, loss of efficiency can also be observed 
with REs ranging from 0.76 to 0.92, and from 0.44 to 0.69, respectively. Generally, the 
relative efficiencies indicate that estimates from the hybrid model are preferable. In 
summary, the hybrid model performs well in correcting partial verification bias and gaining 
efficiency by combining the information from cohort and case-control studies.
4 Case study
4.1 Meta-analysis of Gadolinium-enhanced Magnetic Resonance Imaging (MRI) in 
Detecting Lymph Node Metastases
We reanalyze the meta-analysis conducted by Klerkx et al.16 using the proposed approach. 
Thirty-two studies were reported assessing diagnostic accuracy of gadolinium-enhanced 
MRI in detecting lymph node metastases, with histopathology test as the reference gold 
standard test. A bivariate random effects model6 was applied by Klerkx et al.16 Overall 
sensitivity and specificity were estimated as 0.72 with 95% confidence interval (CI) (0.66, 
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0.79) and 0.87 with 95% CI (0.82, 0.91), respectively. Data for each study is reported in the 
systematic review, as well as the QUADAS21 quality assessment checklist.
The QUADAS criterion is used to classify case-control studies and studies with partial 
verification. The 1st QUADAS criterion is whether patients were representative of practice 
and six studies were reported as “No” or “Not Specified”. These studies are considered as 
case-control studies and the rest as cohort studies in our analysis. The 5th QUADAS 
criterion is whether all subjects were verified by the reference standard or not. Nine cohort 
studies reported as “No”. Among them, we failed to extract missing counts from two studies 
(study 13 and 25 in Table S1 of Appendix 1), thus are treated as having no partial 
verification in the analysis. The remaining seven studies are considered as having partial 
verification. Specific counts of n1m and n0m are extracted for studies 6, 11 and 20. However, 
four studies only indicated total numbers of patients not verified, while specific numbers of 
n1m and n0m are unclear. In practice, efforts should be made to recover missing values. 
Studies with missing values should be discarded to avoid bias. In the MRI study, the original 
papers from studies 10, 15, 16 and 22 were examined but failed to recover missing values. 
However, for purpose of illustration of our method, we assign all missing subjects as 
diagnostic test positive (n0m=0) for simplicity.
4.1.1 Model Fitting via Bayesian Approach—We fit the data using the hybrid GLMM 
with logit link function using WinBUGS44 to draw posterior samples. Model 2 and model 3 
are also fitted for comparison. Non-informative normal priors N(0, 102) are given to η, α 
and β and a Wishart prior W(R, v) is given to the precision matrix Σ−1 as in (5). The degrees 
of freedom v in the Wishart prior is set as v = 4, as pointed out by Tokuda et al. that when v 
= k + 1, where k is the dimension of Σ, the correlation coefficient parameters in Σ will have 
an approximately Uniform (−1, 1) vague prior.45,46 A scaled Wishart prior method is applied 
by setting v = 4 and R as a 3 by 3 identity matrix. Wishart prior is known as a conjugate 
prior for the precision matrix in a multivariate normal distribution. However, it is restricted 
in that it implies the same prior assumption on all of the variance components. The scaled 
Wishart prior method allows the flexibility of having separate priors on each of the precision 
parameter, while keeping the conjugacy property.47 The same priors are applied to model 2 
and model 3. After 100,000 burn-in samples, 1,000,000 posterior samples are collected. The 
median estimates and 95% CrI of interested parameters are presented in Table 3, where the 
estimates from hybrid GLMM are in bold.
The hybrid GLMM gives posterior median estimates of overall sensitivity as 0.76, which is 
0.04 higher than the estimate reported by Klerkx et al.16 and with a slightly narrower 95% 
CI, i.e., an interval of (0.70, 0.82) from the hybrid GLMM versus (0.66, 0.79) from the 
bivariate random effects method. The posterior median is 0.84 for the overall specificity, 
which is 0.03 lower than the bivariate model estimates. In addition, our approach allows the 
estimation of disease prevalence and possible correlations among prevalence, Se and Sp. We 
also presented posterior estimates of PPV, NPV, LR+ and LR− in Table 3. In this case-study, 
the estimates from hybrid GLMM and from model 3 are very similar as only 6 of the 32 
studies are case-control studies, e.g., the median sensitivity is estimated as 0.762 in hybrid 
model and 0.770 in model 3. The quantile contours of posterior estimates Se versus π, Sp 
versus π, Se versus Sp and NPV versus PPV at quantile levels 0.25, 0.5, 0.75, 0.90 and 0.95 
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are presented in Figure 1 A–D, respectively. Figure 1A indicates slightly positive correlation 
between Se and π. Negative correlation can be observed between Sp and π and between Se 
and Sp in Figure 1B and 1C. This observation agrees with the posterior estimates of 
correlation coefficients in Table 3: posterior ρεμ,ρεν and ρμν has median estimates as 0.08, 
−0.42 and −0.47. Slightly negative correlation is shown in Figure 1D between NPV and 
PPV. The observed estimates of Se and Sp for each study and the posterior estimates from 
the hybrid GLMM and model 2 are ploted in Figure 2. The plot shows that different 
approaches can lead to different posterior estimates.
4.1.2 Sensitivity Analysis to Prior Distributions for Σ−1—In addition to the scaled 
Wishart prior, an unscaled Wishart prior is commonly used in which no scale parameter is 
imposed on the precision matrix components. For the unscaled Wishart prior for Σ−1, there 
are several applicable selections of matrix R: the identity matrix,48 or a diagonal matrix with 
diagonal entries chosen to be close to the diagonal elements of posterior precision matrix.36 
In the latter option, previous estimates of the precision matrix can serve as a prior for further 
estimations. As the scaled Wishart prior in Section 4.1.1 gives posterior variance parameter 
estimates close to (0.322, 0,552, 0,912), we choose the Wishart prior parameter R to have 
diagonal entries close to (0.322, 0.552, 0.912)−1 ≈ (9.8, 3.3, 1.2). Thus, to study whether the 
posterior estimates are sensitive to different prior assumptions, we fit the data via two 
unscaled Wishart priors: the identity matrix and a diagonal matrix with elements as (9,8, 3.3, 
1.2). The fitted results are shown in Table 4 under unscaled methods. It shows that different 
priors have little impact on the posterior median Sp or π estimates.
To visually study the impact of different priors on posterior estimates, panel A of Figure 3 
plots posterior densities of Se, Sp and π and panel B of Figure 3 plots posterior densities of 
PPV and NPV under different prior assumptions. Figure 3 shows that different priors have 
little impact on the posterior Sp or π estimates. The unscaled R = diag(9.8, 3.3, 1.2) prior 
gives negligibly larger Se, PPV and NPV posterior estimates than the other two priors. The 
small impact of prior assumption is consistent with intuition and the literature. For example, 
Lambert et al. pointed out that in a univariate setting that relatively large study sizes (15 or 
30 in their simulation settings) would be less influenced by the prior of the scale parameter 
than small study size (5 in their simulation settings).49
4.1.3 An alternative Maximum Likelihood (MLE) approach—A referee has 
suggested considering a frequentist MLE approach as an alternative to obtain parameter 
estimates. Simulation studies comparing the Bayesian and MLE approaches are available in 
the literature.33 We present here the estimates of MRI meta-analysis study via MLE 
approach, which was carried out by SAS NLMIXED procedure. The median estimate is 0.39 
(95% CI: 0.30, 0.45) for disease prevalence, 0.77 (95% CI: 0.70, 0.83) for sensitiviy and 
0.85 (95% CI: 0.80, 0.90) for specificity. The bivariate GLMM8,10,11 ignoring partial 
verification was also fitted via SAS NLMIXED procedure, where sensitivity is estimated to 
be 0.72 (95% CI: 0.66, 0.79) and specificity is estimated to be 0.87 (95% CI: 0.82, 0.92). 
The estimates are close to our posterior estimates from model 1 and model 2 via the 
Bayesian approach (Table 3). The summary receiver operating characteristic (SROC) curves 
was first proposed by Moses et al.50 to reflect the trade-off between sensitivity and 
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specificity caused by implicit thresholds and bigger area under curve (AUC) suggests better 
test performance. SROC curves using the MLE estimates from the hybrid GLMM and the 
bivariate GLMM approaches are plotted for comparison6,12,51 (Figure 2). AUC are estimated 
to be 0.83 and 0.81 from the hybrid GLMM and the bivariate GLMM, respectively. The 
posterior Se and Sp estimates and AUC estimates from the hybrid GLMM and the bivariate 
GLMM ignoring partial verification are different, indicating that ignoring partial verification 
can lead to different conclusions on test accuracy. Thus, it is important to account for partial 
verification in a meta-analysis of diagnostic tests.
4.2 Meta-analysis of adrenal fluorine-18 fluorodeoxyglucose (FDG) positron emission 
tomography (PET) in Characterizing Adrenal Masses
Boland et al. conducted a systematic review and meta-analysis of 21 cohort studies about 
test accuracy of FDG-PET in characterizing adrenal masses.52 The reference standard tests 
used in the 21 cohort studies include surgery, percutaneous biopsy and follow-up CT. FDG-
PET is concluded to be highly accurate in detecting and differentiating malignant adrenal 
disease. The authors applied the bivarate random effects model and reported that the mean 
sensitivity, specificity of FDG-PET are estimated to be 0.97 (95% CI: 0.93, 0.98) and 0.91 
(95% CI: 0.87, 0.94), respectively.52 However, the authors evaluated the methodologic 
quality of the included studies by the QUADAS criterias and 18 out of the 21 studies were at 
risk of partial verification bias. Among the 18 studies with missing counts, we were able to 
extract the total missing counts for 8 studies from the original papers. The cell counts of 
each study are reported in Table S2 of Appendix A. Again, we impose a strong assumption 
on studies with only total missing counts available that the missing subjects were all tested 
negative by FDG-PET. We make this assumption here to creat a violation of the missing 
completely at random situation to show difference in estimates from the hybrid GLMM and 
from model 2. Under this assumption, sensitivity estimates will be conservative. Again, in 
practice, missing values should be recovered as much as possible and studies with missing 
values should be discarded to avoid bias.
We fit this data by the hybrid GLMM and model 2. In both models we use the same priors 
and number of posterior samples as in the meta-analysis of MRI data (section 4.1.1). We do 
not fit this example by model 3, because all the included studies in this meta-analysis are 
cohort studies. The estimates of interesting parameters are presented in Table 4. The hybrid 
GLMM estimates the overall median (95% CrI) sensitivity, specificity and prevalence as 
0.94 (95% CrI: 0.91, 0.97), 0.93 (95% CrI: 0.90, 0.95) and 0.39 (95% CrI: 0.31, 0.47), 
respectively. The overall sensitivity, specificity and prevalence estimates from model 2 are 
0.96 (95% CrI: 0.93, 0.98), 0.90 (95% CrI: 0.87, 0.94) and 0.45 (95% CrI: 0.37, 0.53), 
respectively. The trivariate GLMM ignoring partial verification overestimate sensitivity by 
0.03, underestimate specificity by 0.03 and overestimate prevalence by 0.06. Again, this 
example shows that ignoring partial verification bias can give different estimates for the test 
accuracy parameters.
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5 Discussion
In this paper we propose a hybrid Bayesian hierarchical model to combine cohort and case-
control studies in meta-analysis of diagnostic tests to account for disease prevalence and to 
correct partial verification bias. In general, this approach improves the precision of the 
estimates of test accuracies and predictive values by using all available information, and can 
be easily applied in practice using free downloadable software R53 and WinBUGS.44 The 
WinBUGS code is provided in Appendix C.
Simulation studies are performed under a variety of settings to compare the performance of 
the proposed method with two practical alternative approaches of either ignoring unverified 
subjects or excluding case-control studies. We showed that ignoring unverified subjects can 
lead to substantial bias and excluding case-control studies can lead to substantial loss of 
efficiency. Overall the simulation results show that the hybrid approach gives nearly 
unbiased posterior medians under all settings considered. The coverage probabilities of 
posterior intervals are close to the nominal level. Thus in the presence of mixed study 
designs and partial verification bias in a meta-analysis, the hybrid GLMM should be 
preferred over the two common alternative approaches.
Two case studies are used to illustrate our method. The first case study evaluates the 
diagnostic accuracy of gadolinium-enhanced magnetic resonance imaging in detecting 
lymph node metastases. After combining the case-control and cohort studies and correcting 
for partial verification bias, compared to the original report, slightly higher sensitivity and 
lower specificity point estimates are obtained. The direction of bias on Se and Sp when 
ignoring the missing subjects is opposite of the simulation studies because we assume some 
studies have higher missing probability in MRI tested positives as n0m = 0. This can be 
intuitively explained under an extreme assumption that ωi0m = 0 and ωi1m > 0 such that 
partial verification would decrease ni11 and ni10 but keep ni10 and ni00 the same, leading to 
decreased Se and increased Sp estimates. In addition, our approach provides an overall 
estimate of disease prevalence, which is required for computing other clinical useful indices 
such as PPV and NPV. The second case study evaluates the diagnostic accuracy of FDG-
PET in characterizing adrenal masses. After correcting partial verification bias, the hybrid 
GLMM provides lower sensitivity and prevalence estimates, and higher specificity estimates 
than the bivariate random effects model.
An important question is what is an approriate sample size for such meta-analysis? Our 
simulation settings assumed sample size of 10 and 30 studies and lead to nearly unbiased 
estimates. As we have taken a full Bayesian approach, this becomes an even more intriguing 
question as the needed sample size may depend on whether there are informative priors for 
some parameters to improve estimation. In practice, sample size of meta-analysis varies 
largely. Davey et al.54 summarized that among 22,453 meta-analyses with at least two 
studies, the median number of studies is three and inter-quartile ranges from 2 to 6. As our 
hybrid GLMM is a random effects model, larger sample sizes may be needed.
In this article, we assume that the reference test is a gold standard. In practice, however, the 
reference test may be imperfect and subject to misclassification. Extensions to relax the 
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assumption of perfect reference test are currently under investigation. In such settings, every 
subjects true disease status is unknown and the imperfect tests may be correlated conditional 
on the latent disease status, inducing additional complexity for the estimation of test 
performance. Effort has been devoted in this regard. For example, Chu et al.33 talked about 
adjusting for missing data with imperfect reference test. Dendukuri et al.55 proposed a 
Bayesian approach to access overall sensitivity and specificity under absence of gold 
standard assumption, extending the hierarchical summary receiver operating characteristic 
method by Rutter and Gatsonis.12 Both approaches included conditional dependence 
between the two tests through additional covariance terms. However, restrictions on the 
covariance terms have to be imposed to ensure well-defined probability models.
Another assumption to be relaxed in future research is the MAR assumption. We consider 
the MAR assumption to be practical because in many studies whether a subject is being 
tested by the reference test is merely dependent on the outcome of the diagnostic test and 
other observed characteristics. However, in some studies such as longitudinal studies the 
MNAR assumption may be more appropriate. Baker31 discussed maximum likelihood 
estimates for the situation with multiple tests and Kosinski and Barnhart30 presented a 
general likelihood-based regression approach, based on the conditional selection model by 
Little,56 that can flexibly account for covariates and model different missing data 
mechanisms. Future development is needed to incorporate these approaches in meta-analysis 
settings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Quantile contours of posterior densities from estimates of the meta-analysis of gadolinium-
enhanced MRI in detecting lymph node metastases assuming scaled Wishart prior. A–D plot 
posterior Se versus prevalence (π), Sp versus π, Se versus Sp and PPV versus NPV, 
respectively, at quantile levels 0.25, 0.5, 0.75, 0.9 and 0.95.
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Figure 2. 
SROC curves from the Hybrid GLMM and the bivariate GLMM using MLE approach. Solid 
lines are the SROC curve from the hybrid GLMM estimates and the 95% prediction region 
for the summary point estimates of Se and Sp. Dashed lines are the SROC curve from the 
bivaraite estimates and the 95% prediction region for the summary point estimates of Se and 
Sp. Black and gray circles are the observed Se and Sp from studies with and without missing 
counts, respectively. Red and blue triangles are the posterior estimates of Se and Sp from the 
Hybrid GLMM and the Bivariate GLMM ignoring partial verification, respectively.
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Figure 3. 
Density plots of posterior estimates of the meta-analysis of gadoliniumenhanced MRI in 
detecting lymph node metastases under different prior assumptions. Panel A plots posterior 
densities of Se, Sp and prevalence (π). Panel B plots posteriors densities of PPV and NPV.
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Table 4
Median estimates and 95% CrI for meta-analysis of FDG PET: comparing the hybrid GLMM and model 2 
where partial verification is ignored
Parameter Hybrid GLMM Model 2
π 0.39 (0.31, 0.47) 0.45 (0.37, 0.53)
σε 0.68 (0.47, 1.01) 0.63 (0.43, 0.95)
Se 0.94 (0.91, 0.97) 0.96 (0.93, 0.98)
σμ 0.68 (0.23, 1.51) 0.71 (0.23, 1.54)
Sp 0.93 (0.90, 0.95) 0.90 (0.87, 0.94)
σν 0.54 (0.22, 1.08) 0.51 (0.22, 1)
ρμν 0.78 (−0.37, 0.97) 0.80 (−0.28, 0.97)
ρεμ −0.07 (−0.76, 0.74) −0.05 (−0.80, 0.73)
ρεν −0.46 (−0.89, 0.37) −0.31 (−0.85, 0.49)
NPV 0.96 (0.93, 0.98) 096 (0.93, 0.98)
PPV 0.89 (0.84, 0.93) 0.89 (0.84, 0.93)
LR+ 16.83 (9.94, 37.97) 21.77 (12.85, 49.75)
LR− 0.06 (0.03, 0.10) 0.05 (0.02, 0.08)
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